METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.
Keep Reading
A wearable ring, conversational AI and US$23M in funding. Sandbar wants to rethink how we interact with technology
Updated
April 1, 2026 8:55 AM
Sandbar's Stream ring. PHOTO: SANDBAR
Sandbar, a New York–based interface startup, has raised US$23 million in Series A funding to develop a wearable device that lets people interact with artificial intelligence via voice rather than screens.
Adjacent and Kindred Ventures led the round; both venture firms focused on early-stage technology startups. The investment brings Sandbar’s total funding to us$36 million. Earlier backing included a US$10 million seed round led by True Ventures, a venture capital firm, as well as a US$3 million pre-seed round supported by Upfront Ventures, a venture firm and Betaworks, a startup studio and investment firm.
Sandbar was founded by Mina Fahmi and Kirak Hong, who previously worked together at CTRL-labs, a neural interface startup acquired by Meta in 2019. Their earlier work explored how computers could respond more directly to human intent — an idea that continues to shape Sandbar’s approach to AI interfaces.
The new funding will help the company expand its team across machine learning, interaction design and software engineering as it prepares to launch its first product. That product, called Stream, combines a wearable ring with a conversational AI interface. The system allows users to speak to an AI assistant without unlocking a phone or opening an app.
The concept is simple. Instead of typing into a screen, users press a button on the ring and talk. The system can capture notes, organize ideas, retrieve information from the web or trigger actions through connected applications.
The ring includes a microphone, a touchpad and subtle haptic feedback. These elements allow the device to respond through gentle vibrations rather than visual alerts. According to the company, the ring only listens when the user presses the button — a design meant to address common concerns around always-on microphones.
That design reflects a larger shift Sandbar believes is underway. As AI assistants become more capable, many startups are experimenting with new ways to interact with them. The focus is moving away from screens and keyboards toward interfaces that feel more natural and immediate.
Stream uses multiple AI models working together to process requests, search the web and structure information in real time. The company says users remain in control of their data and can choose whether to share information with other apps.
Sandbar is also developing a feature called Inner Voice, which responds using a voice customized to the user. The feature will debut during a closed beta planned for this spring, giving the company time to refine how the software behaves in everyday use.
The startup currently employs a team of 15 people. Many have worked on well-known consumer devices including the iPhone, Fitbit, Kindle and Vision Pro. Recent hires include Sam Bowen, formerly of Amazon and Fitbit, who joined as vice president of hardware and Brooke Travis, previously at Equinox, Dior and Gap, who now leads marketing.
Sandbar plans to begin shipping Stream in summer 2026 after completing early testing. As artificial intelligence tools become more integrated into daily life, the company is betting that the next shift in computing will not come from another app — but from new ways for people to interact with AI itself.